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Abstract:  
BACKGROUND & AIMS: The DnaJ (Hsp40) homolog, subfamily B, member 6 
(DNAJB6) is part of a family of proteins that regulate chaperone activities. One 
of its isoforms, DNAJB6a, contains a nuclear localization signal and regulates 
β-catenin signaling during breast cancer development. We investigated the 
role of DNAJB6 in pathogenesis of esophageal squamous cell carcinoma 
(ESCC).  
 
METHODS: We performed immunohistochemical analyses of primary ESCC 
samples and lymph node metastases from a cohort of 160 patients, who 
underwent esophagectomy with no pre-operative chemo-radiotherapy at Hong 
Kong Queen Mary Hospital. Data were collected on patient outcomes over a 
median time of 12.1±2.9 months. Retrospective survival association analyses 
were performed. Wild-type and mutant forms of DNAJB6a were overexpressed 
in cancer cell lines (KYSE510, KYSE 30TSI, KYSE140, and KYSE70TS), 
which were analyzed in proliferation and immunoblot assays, or injected 
subcutaneously into nude mice. Levels of DNAJB6 were knocked down in 
ESCC cell lines (KYSE450 and T.Tn), immortalized normal esophageal 
epithelial cell lines (NE3 and NE083), and other cells with short hairpin RNAs 
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or by genome engineering. Bimolecular fluorescence complementation was 
used to study interactions between proteins in living cells.  
 
RESULTS: In primary ESCC samples, patients whose tumors had high 
nuclear levels of DNAJB6 had longer overall survival times (19.2±1.8 months; 
95% confidence interval [CI], 15.6–22.8 months) than patients whose tumors 
had low nuclear levels of DNAJB6 (12.6±1.4 months; 95% CI, 9.8–15.4 
months; P=.004, by log rank test). Based on Cox regression analysis, patients 
whose tumors had high nuclear levels of DNAJB6 had a lower risk of death 
than those with low levels (hazard ratio=0.562; 95% CI, 0.379–0.834; P=.004). 
Based on log rank analysis and Cox regression analysis, the combination of 
nuclear level of DNAJB6 and the presence of lymph node metastases at 
diagnosis could be used to stratify patients into groups with good or bad 
outcomes (P<.0005 for both analyses). There was a negative association 
between the nuclear level of DNAJB6 and the presence of lymph node 
metastases (P=.022; Pearson χ2 test). Cancer cell lines that overexpressed 
DNAJB6a formed tumors more slowly in nude mice than control cells or cells 
that expressed a mutant form of DNAJB6a that did not localize to the nucleus. 
DNAJB6 knockdown in cancer cell lines promoted their growth as xenograft 
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tumors in mice. A motif of histidine, proline, and aspartic acid (HPD) in the J 
domain of DNAJB6a was required for its tumor suppressive effects and 
signaling via AKT1. Loss of DNAJB6a resulted in upregulation of AKT signaling 
in cancer cell lines and immortalized esophageal epithelial cells. Expression of 
a constitutively active form of AKT1 restored proliferation to tumor cells that 
overexpressed DNAJB6a, and DNAJB6a formed a complex with AKT1 in living 
cells. Expression of DNAJB6a reduced the sensitivity of ESCC to AKT 
inhibitors; the expression level of DNAJB6a affected AKT signaling in multiple 
cancer cell lines. 
 
CONCLUSIONS: Nuclear localization of DNAJB6 is associated with longer 
survival times of patients with ESCC. DNAJB6a reduces AKT signaling, and 
DNAJB6 expression in cancer cells reduces their proliferation and growth of 
xenograft tumors in mice. DNAJB6a might be developed as biomarker for 
progression of ESCC. 
 
KEYWORDS: prognostic marker; tissue microarray; signal transduction; tumor 
suppressor 
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INTRODUCTION 
Esophageal carcinoma ranks as the eighth most frequent cancer 
worldwide, with an estimated 9% age-standardized incidence rate and 7.7% 
age-standardized mortality rate in 2012.1 It is classified into two major 
histologic forms including esophageal squamous cell carcinoma (ESCC) and 
esophageal adenocarcinoma (EAC). EAC is more frequent in developed 
Western countries, while ESCC is the dominant histologic type in Asia 
including China and Hong Kong.2  
The DNAJ/HSP40 family functions as co-chaperones, which modulate the 
activity and substrate specificity of chaperone proteins such as the HSP70 
families. DNAJB6 is a member of the HSP40/DNAJ family. Two variants 
resulting from alternative splicing exist resulting in two protein isoforms, 
DNAJB6a and DNAJB6b.3 Mutation of DNAJB6b has been detected and 
studied in limb-girdle muscular dystrophy.4  
We reported the role of DNAJB6a in breast cancer is related to the 
regulation of the GSK3β/β-catenin pathway.5-7 Herein, we studied the 
expression of DNAJB6 and correlates with the clinicopathological features of 
ESCC. The DNAJB6 nuclear isoform, DNAJB6a, was studied in vivo and in 
vitro to reveal its mechanisms in ESCC. 
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Materials and Methods details are in Supplementary Materials 
 
Results 
Nuclear DNAJB6 level is an independent prognostic marker for better 
survival 
Kaplan-Meier survival analysis showed that high nuclear levels of 
DNAJB6 (DNAJB6_Hi) in primary tumors (n=160) were significantly correlated 
with better overall patient survival (median survival ± standard error: 19.2±1.8 
months; 95% confidence interval [CI], 15.6-22.8 months) compared to low 
level (DNAJB6_Lo) (12.6±1.4 months; 95%CI, 9.8-15.4 months; P=.004 by 
Log-rank test, Figure 1A; Representative images shown in Supplementary 
Figure 1). Univariate Cox regression analysis showed that patients with high 
nuclear DNAJB6 levels have reduced risk of death (hazard ratio [HR] = 0.562, 
95%CI, 0.379-0.834, P=.004), as compared to patients with low levels (HR=1). 
Multivariable Cox regression analysis confirmed nuclear DNAJB6 level is a 
predictor for overall survival (P=.025), independent from pathological stage, 
presence of lymph node metastases, and M stage (Table 1). These data 
suggest a general protective role of nuclear DNAJB6 in ESCC.   
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Combination of nuclear DNAJB6 level and status of lymph node 
metastasis at diagnosis could be used to stratify patients into two 
groups with differential risks of death 
To further characterize possible associations behind the beneficial survival 
effect of nuclear DNAJB6 level, interaction tests with other prognostic clinical 
parameters were performed. Nuclear DNAJB6 level showed significant 
interaction with presence of lymph node metastasis (P<.05, Supplementary 
Table 1) and with M stage (P<.0005). Given the very limited sample size for M1 
patients (n=12), we focused only on lymph node metastasis and further 
performed survival analyses regarding nuclear DNAJB6 level and presence of 
lymph node metastasis.  
Kaplan-Meier survival analysis confirmed that the presence of lymph node 
metastases (LNM_+ve versus LNM_-ve) was significantly correlated with 
worse patient overall survival (n=99; 12.2±2.1 months; 95%CI, 8.1-16.3 
months versus n=61; 23.1±4.1 months; 95%CI, 15.1-30.0 months, P=.003, 
Supplementary Figure 2). Indicated by the interaction test, we also confirmed 
that among patients without lymph node metastasis (n=61), nuclear DNAJB6 
level still possesses prognostic value (P=.003, Supplementary Figure 3). We 
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further stratified the entire cohort into two groups according to their status of 
nuclear DNAJB6 level and lymph node metastasis. Interestingly, Kaplan-Meier 
survival analysis showed that patients with high nuclear DNAJB6 levels and no 
lymph node metastasis (DNAJB6_Hi/LNM_-ve) (n=33) displayed much better 
survival profiles (43.1±13.6 months; 95%CI, 16.4-69.7 months; P<.0005; 
Figure 1B), as compared to other patients either with low nuclear DNAJB6 
level or with lymph node metastasis (DNAJB6_Lo or LNM_+ve, n=137; 
13.15±1.5 months; 95%CI, 10.2-16.1 months). Univariate Cox regression 
analysis showed that patients with high nuclear DNAJB6 levels and no lymph 
node metastasis have significantly reduced risk of death (HR=0.359; 95%CI, 
0.209-0.616; P<.0005), as compared to other patients (HR=1). This suggests 
that the combination of nuclear DNAJB6 level together with lymph node 
metastasis status at diagnosis serve as predictive indicators to stratify patients 
in two groups with very distinct prognostic features.  
 
Nuclear DNAJB6 level in primary tumor is associated with presence of 
lymph node metastasis 
We also found that patients with low nuclear DNAJB6 levels were more 
likely to have lymph node metastases, compared to patients with high levels 
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(P=.022, 2-sided by Pearson Chi-Square test, Supplementary Table 2). 
However, in the 25 pairs of matched primary tumor/ lymph node 
metastases, 64% (16 pairs) showed comparable and 36% (9 pairs) showed 
differential nuclear DNAJB6 levels. Overall, nuclear DNAJB6 level is 
comparable between primary tumor and lymph node metastasis, suggesting 
loss of nuclear DNAJB6-mediated tumor-suppressive function occurs early 
before metastasis.  
 
DNAJB6a encodes nuclear DNAJB6 and is downregulated in ESCC 
There are two isoforms of DNAJB6, DNAJB6a and DNAJB6b, differing in 
their carboxy terminal sequences. A functional nuclear localization signal (NLS) 
was present in DNAJB6a5 (Supplementary Figure 4). The presence of a 
functional nuclear export signal (NES) has not been reported for DNAJB6b. 
The subcellular localization of DNAJB6 in ESCC was examined by expressing 
fluorescence fusion proteins in two cell lines (Supplementary Figures 5 and 6). 
Wild type (WT) DNAJB6a was mainly concentrated in the nucleus, while WT 
DNAJB6b diffuses throughout the cell. DNAJB6a ∆NLS loses the ability to 
reside in the nucleus completely, indicating a functional NLS in DNAJB6a in 
ESCC. The data also suggest a functional NES in DNAJB6b. These results 
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suggest that the nuclear DNAJB6 staining pattern in the tissue microarray 
(TMA) analysis mainly corresponds to the DNAJB6a isoform. 
Expression of the DNAJB6a transcript was significantly downregulated in 
two sets of esophageal non-tumor/tumor tissue samples by hybridization–
based oligonucleotide microarray analysis (GSE20347 and GSE29001) (probe 
209015_s_at; P<.001 and =.030, respectively), but not the DNAJB6b transcript 
(probe 208810_at; P=.554 and .727, respectively) (Figure 1 ). Expression of 
the DNAJB6a transcript was downregulated in 56.3% (9/16) and upregulated 
in 18.8% (3/16) of ESCC cell lines using an immortalized normal esophageal 
epithelial (NE) cell line, NE3, as a reference (Supplementary Figure 7). The 
expression of the DNAJB6b transcript does not show significant alteration.  
 
DNAJB6a expression level affects tumorigenesis in mouse model and 
proliferation in a variant-specific and localization-dependent manner 
DNAJB6a expressions were restored by over-expression in four 
tumorigenic cell lines with downregulated endogenous DNAJB6a expression, 
namely KYSE510/30TSI/140/70TS, and cells were injected subcutaneously 
into the mice and compared with cells expressing vector-alone (VA), diffusely 
localized DNAJB6b, and mislocalized DNAJB6a containing the deletion of the 
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NLS (DNAJB6a ∆NLS), as controls. Only the WT DNAJB6a over-expressing 
cells produce smaller tumors and display a 2- to 4-week lag period for tumor 
growth (Figure 2A, Supplementary Figures 8 and 9). Two cell lines, KYSE510 
and KYSE30TSI, showing greater tumor-suppressive effects by DNAJB6a 
expression, were used for further functional and mechanistic analyses. 
Reversely, endogenous DNAJB6a expression knockdown in KYSE450 and 
T.Tn cell lines enhances in vivo tumor growth (Figures 2A, Supplementary 
Figure 10). These data collectively demonstrate that the expression of the 
nuclear DNAJB6 protein affects tumorigenicity in vivo, as observed with the 
TMA.  
In vitro cell viability was assessed. WT DNAJB6a-over-expressing cells 
proliferate more slowly compared to VA, DNAJB6a ∆NLS, and DNAJB6b- 
over-expressing cells (Figure 2B, Supplementary Figure 11). DNAJB6a 
knockdown also results in increased proliferation (Figure 2B, Supplementary 
Figure 12). These data show the inhibitory effects of DNAJB6a on cell 
proliferation.  
Flow cytometry study was performed to examine possible cell cycle 
regulation by DNAJB6a. After release from G1 synchronization, cells 
over-expressing DNAJB6a progress at a reduced rate towards G2 phase, as 
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compared to control cells (Figure 2C), while DNAJB6a knockdown promotes 
progression. As a control, cells over-expressing DNAJB6a go through mitosis 
at a comparable rate compared to control cells (Supplementary Figure 13).  
 
DNAJB6a regulates AKT signaling in cancer cells 
Consistent with the aforementioned results, the protein expression of 
cyclin E1 is downregulated in DNAJB6a over-expressing cells compared to VA 
cells both in vivo and in vitro (Figure 3A). DNAJB6a knockdown also 
upregulates cyclin E1 protein expression level in vivo and in vitro (Figure 3B). 
This is consistent with a previous finding that downregulation of cyclin E1 by 
microRNA reduced tumor growth and cell proliferation in ESCC.8 
One of the major signaling pathways that regulates cyclin E1 protein 
expression is the AKT1/P27KIP1 pathway.9-12 The phosphorylation status of 
threonine 308 (T308) and serine 473 (S473) of AKT1 was examined. 
Downregulation of phosphorylated AKT1, along with P27KIP1 upregulation, 
was observed in both in vivo and in vitro DNAJB6a-over-expressing cells 
(Figure 3A). Reduced DNAJB6a expression upregulates AKT1 
phosphorylation and downregulates P27KIP1 in vivo and in vitro (Figure 3B). 
These data suggest that DNAJB6a acts through AKT1 to regulate P27KIP1, 
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leading to regulation of cyclin E1 protein expression.  
To investigate the causality between cyclin E1 protein expression and 
AKT1 phosphorylation in ESCC, the effect of IGF-1, a well-known AKT1 
pathway activator, on cells over-expressing DNAJB6a was investigated. The 
results show cyclin E1 protein expression is upregulated upon AKT1 activation 
by IGF-1, and AKT1 activation abolishes the down-regulation of cyclin E1 
protein expression by DNAJB6a over-expression, indicating that cyclin E1 
protein expression is downstream and a consequence of AKT1 activation in 
ESCC (Figure 3C). An AKT1 inhibitory assay was performed in 
DNAJB6a-knockdown cells. AKT inhibition abolishes the upregulation of cyclin 
E1 protein expression by DNAJB6a knockdown, further confirming a regulatory 
role of AKT1 on cyclin E1 protein expression (Figure 3D).  
 
DNAJB6a regulates AKT signaling in immortalized normal cells 
TMA analysis showed no significant difference of nuclear DNAJB6 level 
related to early/late T-stage (P=.630, 2-sided by Pearson Chi-Square test, 
Supplementary Table 2), suggesting that loss of nuclear DNAJB6-mediated 
tumor-suppressive effect may occur early in ESCC development. We 
examined the role of DNAJB6a in precancerous cells using two NE cell lines 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 17 of 39 
 
(NE3 and NE083) for DNAJB6a knockdown. DNAJB6a knockdown in NE cells 
increases AKT1 phosphorylation and upregulates the protein expression level 
of cyclin E1 (Figure 3E). AKT1 inhibition diminishes the upregulation of cyclin 
E1 protein expression by DNAJB6a knockdown (Figure 3F). This suggests that 
the DNAJB6a AKT1 regulatory effect generally applies under different 
circumstances.  
 
Loss of DNAJB6a by variant-specific functional knockout (fKO) 
upregulates AKT signaling and enhances proliferation 
Considering the possible non-specific targeting of mRNA variants by short 
hairpin RNA knockdown, the newly developed CRISPR-Cas9 genome 
engineering tool13 was utilized to interfere with DNAJB6 protein expression by 
targeting a variant-specific exon leading to variant-specific sequence 
alterations (Supplementary Figure 4). Western blotting confirmed 
isoform-specific loss of DNAJB6 by variant-specific targeting oligo (Figure 4A). 
Consistent with the DNAJB6a knockdown results, DNAJB6a fKO upregulates 
AKT1 phosphorylation and cyclin E1 protein expression (Figure 4B) and 
enhances cell proliferation (Figure 4C, Supplementary Figure 14). The results 
further confirmed specific AKT regulation by the DNAJB6a isoform. 
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Proliferation and cell cycle regulation by DNAJB6a is AKT-dependent 
To examine the causality between AKT regulation and proliferation 
inhibition by DNAJB6a, a myr-tagged constitutively active AKT1 construct 
(myrAKT) was introduced in DNAJB6a over-expressing cells to restore the 
down-regulated AKT activity. AKT activity rescue significantly eliminates the 
proliferation inhibitory effect (Figure 4D, Supplementary Figure 15), the cell 
cycle progression suppression (Figure 4E), and p27/cyclin E1 protein 
expression down-regulation (Figure 4F) in DNAJB6a over-expressing cells. 
The results strongly indicate that DNAJB6a acts through AKT activity 
regulation to inhibit proliferation and, thus, tumor suppression. Proliferation 
inhibition by DNAJB6a is AKT-dependent.  
 
The HPD motif in the J domain is crucial for AKT signaling regulation and 
tumor-suppressive effects of DNAJB6a 
DNAJ/HSP40 proteins rely heavily on the J domain containing a highly 
conserved tripeptide of histidine/proline/aspartic acid residues (HPD motif) for 
proper functioning. Therefore, a HPD motif dead DNAJB6a mutant, in which 
the tripeptide was changed to three alanines (AAA), was utilized to 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 19 of 39 
 
characterize the molecular basis for DNAJB6a function in ESCC. Introduction 
of the mutant greatly abolishes the in vivo tumor-suppressive effect of WT 
DNAJB6a, as mutant over-expressing cells share similar growth kinetics with 
the control cells in mouse (Figure 5A, Supplementary Figure 16). Introduction 
of the mutant also abolishes the inhibitory effect on in vitro cell proliferation 
(Figure 5B, Supplementary Figure 17) and the regulation of both AKT1 
phosphorylation and cyclin E1 protein expression (Figure 3A). These data 
demonstrate the critical role of the HPD motif in DNAJB6a-dependent tumor 
suppression in ESCC. 
 
Protein phosphatase 2A (PP2A) activity is required for AKT signaling 
regulation of DNAJB6a 
Inhibition of PP2A, a well-studied modulator of AKT1 phosphorylation,14, 15 
was applied to DNAJB6a over-expressing cells to investigate the involvement 
of PP2A phosphatase activity in the downregulation of AKT1 phosphorylation. 
Inhibition of PP2A phosphatase activity by treatment of a PP2A inhibitor 
okadaic acid (OA) greatly abolishes the downregulation of AKT1 
phosphorylation by DNAJB6a over-expression in cell lines tested (Figure 5C), 
suggesting the requirement of PP2A phosphatase activity in AKT1 regulation 
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by DNAJB6a. 
 
DNAJB6a complexes with AKT1 in living cells 
To examine potential protein-protein interaction/complexing between 
DNAJB6a and AKT1 in living cells, a bimolecular fluorescence 
complementation (BiFC) live-cell imaging assay16 was utilized. Remarkably, 
cells expressing the PAS-AKT1WT fusion protein together with the 
DNAJB6aWT-GAFm fusion proteins (PAS-AKT1WT/DNAJB6aWT-GAFm) 
showed significantly more NIR fluorescence signal-positive cells with distinct 
nuclear patterns (Figure 5D, Supplementary Figure 18), indicating an 
interaction/complexing between AKT1 and DNAJB6a. Consistent with the 
AKT1 regulation analysis, using the mutant DNAJB6a construct 
(DNAJB6a-AAA), cells co-expressing PAS-AKT1WT/DNAJB6aAAA-GAFm 
fusion proteins showed few NIR fluorescence signals. Introduction of a mutant 
AKT1 protein (K179M/T308A/S473A; MAA) fused to PAS domain also 
diminishes the protein complexing potential with DNAJB6a, when 
co-expressed with DNAJB6aWT-GAFm fusion protein in cells. These findings 
indicate that AKT1 and DNAJB6a can specifically form a complex in living 
cells. 
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DNAJB6a modulates cell sensitivity to AKT inhibition 
Upon pharmaceutical AKT inhibition, ESCC cells over-expressing 
DNAJB6a became less sensitive to inhibition and showed a significantly higher 
viability, while in contrast, cells with DNAJB6a-knockdown showed significantly 
higher sensitivity and lower viability, as compared to control cells, respectively 
(Figure 6A). As a control, cells did not show alteration of sensitivity to inhibition 
of the mitogen-activated protein kinase. These results suggest that modulation 
of AKT1 phosphorylation by DNAJB6a confers opposing functional 
consequences to the survival of the cells upon inhibition of the AKT signaling.  
 
DNAJB6a modulates AKT signaling in other type of cancer cells 
The possibility that DNAJB6a acts as a more general AKT regulator in 
various cell lines was tested for various cancer/tissue types by DNAJB6a 
over-expression or knockdown. Interestingly, DNAJB6a regulates AKT 
signaling only in a subset of cell lines, including A549, HepG2, HONE1, and 
NP460 cells, but not in others (Figure 6B). Therefore, these data suggest that 
DNAJB6a may act as a general AKT regulator in a tissue-specific manner. 
We further examined the expression levels of DNAJB6a transcripts in 
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other cancers using publicly available microarray data. Interestingly DNAJB6a 
expression is down-regulated in EAC, another major subtype of esophageal 
cancer. We did not observe significant down-regulation of DNAJB6a 
transcripts in other cancer types (Supplementary Figure 19).  
 
Over-expression of DNAJB6a does not suppress lung colonization in a 
distant metastasis mouse model 
To explore the functional effect of DNAJB6a on metastasis, a tail-vein 
metastasis mouse model was utilized. In vivo bioluminescent imaging showed 
that cells over-expressing DNAJB6a colonize the lungs of the mice at a 
comparable rate as compared to cells over-expressing VA (Supplementary 
Figures 20 and 21). The survival data also showed consistency with the 
imaging result. Mice injected with cells over-expressing DNAJB6a share 
similar survival dynamics (P=.496 by Log-rank test, Supplementary Figure 22). 
These data indicate that expression of DNAJB6a elicits no inhibitory effect on 
metastasis, as opposed to that on primary tumor. 
 
Discussion 
This study provides the first evidence of a tumor-suppressive role of 
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DNAJB6 in ESCC. The TMA analysis indicates that nuclear DNAJB6 is an 
independent indicator for better overall survival in Hong Kong ESCC patients. 
We also found that there is significant interaction between nuclear DNAJB6 
level and presence of lymph node metastasis. Furthermore, combining the 
status of nuclear DNAJB6 level and lymph node metastasis at diagnosis could 
be used to stratify ESCC patients into two groups with significantly differential 
risks of death and outcomes.     
We showed that DNAJB6a localizes to the nucleus due to the existence of 
a functional NLS at the C-terminal end and DNAJB6b diffuses throughout the 
cell in ESCC. Therefore, the observed nuclear DNAJB6 staining pattern in 
tumor specimens corresponds mostly to the DNAJB6a isoform. Cell line-based 
models showed that the tumor-suppressive effect is isoform-specific. 
Consistent with the TMA result, only over-expression of nucleus-localized WT 
DNAJB6a induces in vivo tumor suppression and in vitro proliferation inhibition. 
This is consistent with our previous findings that DNAJB6a suppresses tumor 
growth in breast cancer.5, 7 By introducing a constitutively active AKT1 
construct to compensate for the down-regulated AKT1 activity in DNAJB6a 
over-expressing cells, we showed that the proliferation inhibition induced by 
DNAJB6a is AKT1-dependent, indicating that DNAJB6a acts through AKT1 
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regulation to inhibit proliferation and, thus, tumor suppression. In our previous 
studies, DNAJB6a was reported to regulate the Wnt/β-Catenin signaling.6, 7 
This indicates that DNAJB6a plays a tissue-specific role. 
The current study revealed a novel AKT signaling regulation by a member 
of the DNAJ/HSP40 family in cancer. As a major oncogenic player, continuous 
activation of AKT signaling usually results from aberrant upstream signals that 
phosphorylate AKT1 at T308 and S473.17 Phosphorylation at both sites is 
strictly controlled by interactions with kinases and phosphatases.18 The AKT 
signaling pathway is highly activated in ESCC through over-expression, 
amplification, and mutation events.19 We showed that the DNAJB6a regulates 
phosphorylation of AKT1 and the dependent downstream effects and a 
functioning protein phosphatase PP2A is needed for such regulation (Figure 
6C). We also showed AKT signaling regulation by DNAJB6a expression in 
normal immortalized esophageal epithelial cells, indicating that loss of 
DNAJB6a in precancerous tissues may elicit oncogenic features.  
Mechanistically, the analyses using mutant DNAJB6a in functional and 
molecular analysis showed for the first time in ESCC that the tumor 
suppression of DNAJB6a essentially relies on the HPD motif in the J-domain. 
Members of the DNAJ/HSP40 family bind and stimulate the ATP-hydrolysis 
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activity of HSP70 through the highly conserved HPD motif in J-domain.20-22 
Utilizing a NIR fluorescent protein-based BiFC imaging assay, we showed that 
DNAJB6a and AKT1 specifically form complexes in living cells in a HPD 
motif-dependent manner. We also confirmed that DNAJB6a interacts with 
HSP70 using the co-immunoprecipitation assay in ESCC cells (Supplementary 
Figure 23). In our previous study, we showed that DNAJB6a interacts with the 
PP2A catalytic subunit in cancer cells.7 HSP70 has been implicated to interact 
with PP2A.23, 24 Therefore, we propose a mechanistic hypothesis that 
DNAJB6a complexes with HSP70/PP2A/AKT1 in the nucleus and promotes 
dephosphorylation of AKT1 by PP2A.  
DNAJB6a expression also modifies cellular sensitivity to AKT inhibition by 
a small molecule inhibitor. Increasing DNAJB6a expression level leads to 
downregulated AKT signaling but also decreased sensitivity to AKT inhibition, 
and vice versa, suggesting that ESCC cells adapt to elevated oncogenic 
signaling and gain addiction. This suggests that AKT hypoactivation by 
DNAJB6a and AKT inhibition by a chemical inhibitor does not work 
synergistically, which may provide insight into molecular targeted therapy 
focusing on oncogene addiction. 
In order to examine whether the effect on AKT signaling regulation of 
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DNAJB6a is ESCC-specific or represents a more general phenomenon, 
several cell lines from other cancer types or immortalized normal cells were 
studied. DNAJB6a expression modulation regulates AKT1 phosphorylation in 
four of the eight cell lines tested, indicating a tissue-specific role. This is akin to 
the reported tissue-specific expression of various PP2A regulatory subunits25. 
Intriguingly, in a recent study by Zhang et al., DNAJB6 expression was found 
to be oncogenic and to promote invasion in colorectal cancer in SW480,26 
consistent with our data for a tissue-specific role. However, we did not observe 
significant down-regulation of DNAJB6a transcripts in clinical samples of other 
cancer types. This may be due to the complexities of different cancers in which 
DNAJB6a plays different roles. Further studies on DNAJB6a protein 
expression levels and functional studies are needed to fully assess its 
functional impact in these cancer types. Interestingly, DNAJB6a shows 
significant down-regulation in EAC clinical samples, similar to ESCC, 
indicating that generally in esophageal cancer DNAJB6a likely plays an 
important tumor-suppressive role. Detailed functional and molecular assays of 
DNAJB6a in EAC are warranted.   
The mouse model indicated that DNAJB6a does not possess suppressive 
effects in distant metastasis. A previous study indicated that AKT1 activated by 
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the chemokine receptor CXCR4 in oral squamous cell carcinoma promoted 
lymph node metastasis, but not distant metastasis27. These data suggest a 
differential role of DNAJB6a, likely involving AKT-regulated signaling in primary 
tumor growth, lymph node metastasis, and distant metastasis.  
The current study is, however, limited by several factors. Firstly, patients 
enrolled in the study were from a single institute. A larger multi-institutional 
validation cohort is needed to verify the clinical utility of using the DNAJB6 
level as predictive indicators. Secondly, due to the limited sample size, 
subgroup analysis lacked substantial statistical power. Furthermore, there is 
currently no available mouse sporadic ESCC model for detailed examination of 
functional and molecular properties of DNAJB6. 
This study shows that nuclear DNAJB6 is a tumor suppressor in ESCC 
and plays a critical role in the development of primary ESCC. This study also 
provides new insights into the regulation of AKT signaling and suggests the 
potential for the usefulness of DNAJB6 as a prognostic and therapeutic 
biomarker for ESCC. 
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Figure Legends 
Figure 1. Nuclear DNAJB6 expression as a good prognostic marker. (A) 
Kaplan-Meier analysis showed that nuclear DNAJB6 level was a prognostic 
marker. (B) Kaplan-Meier analysis showed that nuclear DNAJB6 level together 
with presence of lymph node metastasis could be used to further stratify 
patients into different groups with distinct survival outcomes. (C) DNAJB6a 
transcript was significantly downregulated in two sets of ESCC 
non-tumor/tumor specimens. 
Figure 2.  Suppression of tumor growth and cell proliferation of DNAJB6a.  
(A) Summary of in vivo tumor growth of DNAJB6-over-expressing or 
DNAJB6a-knockdown cells in subcutaneous tumorigenicity mouse models. 
For individual growth curves and protein expressions see Figure 3B and 
Supplementary Figures 7-9. Time points presented: week 4 for KYSE510, 
KYSE30TSI, and KYSE140; week 3 for KYSE70TS; week 5 for KYSE450 and 
T.Tn. (B) Summary of in vitro proliferation. For individual growth curves see 
Supplementary Figures 10 and 11. Time points presented: day 5 for KYSE510, 
KYSE450, and T.Tn; day 6 for KYSE30TSI. (C) Cell cycle progression after 
release from G1 synchronization. Recovery time: 18 hours for KYSE510; 30 
hours for KYSE30TSI; 23 hours for KYSE450; 20 hours for T.Tn. #: adjusted 
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P<.1; ##: adjusted P<.05; ###: adjusted P<.01; ####: adjusted P<.001; n.s.: 
adjusted P>.1. ***: P<.001; ctrl: non-targeting control oligo. 
Figure 3. AKT signaling regulation of DNAJB6a. (A) Western blotting shows 
downregulated cyclin E1 protein expression and AKT1 phosphorylations with 
upregulated p27KIP1 protein expression in DNAB6a-over-expressing cells 
both in vivo and in vitro. Introduction of HPD motif dead mutant (AAA) greatly 
abolished the regulation of AKT signaling. (B) Western blotting showed 
upregulated cyclin E1 protein expression and AKT1 phosphorylations with 
downregulated p27KIP1 protein expression in DNAJB6a-knockdown cells both 
in vivo and in vitro. (C) Western blotting showed that cyclin E1 protein 
expression is upregulated after AKT1 activation by IGF-1, and that AKT1 
activation greatly abolishes the downregulation of cyclin E1 protein expression 
by DNAJB6a over-expression. (D) Western blotting revealed that AKT 
inhibition (AKTi) diminishes the upregulation of cyclin E1 protein expression in 
DNAJB6a-knockdown cells. (E) Western blotting showed upregulated cyclin 
E1 protein expression and AKT1 phosphorylations with downregulated 
p27KIP1 protein expression in DNAB6a-knockdown NE cells. (F) Western 
blotting shows that AKT inhibition diminishes the upregulation of cyclin E1 
protein expression in DNAJB6a-knockdown NE cells. VA: vector-alone; Da: 
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DNAJB6a; ctrl: non-targeting control oligo; shDa: DNAJB6a knockdown. 
Figure 4. Isoform-specific DNAJB6a fKO assay and AKT activity rescue assay. 
(A) Western blotting confirms isoform-specific loss of DNAJB6a/b by 
variant-specific targeting oligos. (B) Western blotting shows DNAJB6a fKO 
upregulates AKT signaling. (C) Summary of in vitro proliferation of DNAJB6a 
fKO cells. For individual cell line growth curves see Supplementary Figure 13. 
Time points presented: day 5 for KYSE450 and T.Tn. (D) Summary of in vitro 
proliferation of cells expressing constitutively active AKT1 construct. For 
individual cell line growth curves see Supplementary Figure 14. Time points 
presented: day 5 for KYSE510 and day 7 for KYSE30TSI. (E) Cell cycle 
progression after release from G1 synchronization of AKT activity rescued 
cells. Recovery time: 20 hours for KYSE510; 28 hours for KYSE30TSI; (F) 
Western blotting shows that the molecular changes induced by DNAJB6a 
expression are reversed by AKT activity rescue. #: adjusted P<.1; ##: adjusted 
P<.05; ###: adjusted P<.01; ctrl: non-targeting control oligo; sgRNA1 and 
sgRNA2: sgRNA specifically targets DNAJB6a. myrAKT: myr-tagged 
constitutively active AKT1 construct; VA: vector-alone; Da: DNAJB6a 
expression; Da+: DNAJB6a expression with constitutively active AKT1 
expression. 
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Figure 5. Mechanistic analysis of AKT signaling regulation of DNAJB6a. (A) 
Summary of in vivo tumor growth of WT and mutant DNAJB6a (AAA) 
over-expressing cells in subcutaneous mouse models. For individual cell line 
growth curves and protein expressions see Figure 3A and Supplementary 
Figure 15. Time points presented: week 4 for KYSE510 and week 5 for 
KYSE30TSI. (B) Summary of in vitro proliferation. For individual cell line 
growth curves see Supplementary Figure 16. Time points presented: day 5 for 
KYSE510 and day 7 for KYSE30TSI. The in vivo tumor growth and in vitro 
proliferation profiles of VA and WT DNAJB6a over-expressing cells of 
KYSE510 and KYSE30TSI in (A) and (B) were duplicated from Figure 2A and 
2B, respectively, as these data were generated from the same batches of 
samples. (C) PP2A inhibition by OA treatment greatly abolished the regulation 
of AKT1 phosphorylation by DNAJB6a over-expression. (D) Summary of 
NIR-positive cell percentages of images from cells expressing different pairs of 
fusion proteins. Cells expressing the PAS-AKT1WT fusion protein with the 
DNAJB6aWT-GAFm fusion protein (AKT1WT/DNAJB6aWT) showed 
significantly more NIR fluorescence signal- positive cells, as compared to cells 
expressing mutants of either protein (AKT1MAA/DNAJB6aWT and 
AKT1WT/DNAJB6aAAA). ##: adjusted P<.05; ###: adjusted P<.01; ####: adjusted 
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P<.001; n.s.: adjusted P>.1. 
Figure 6. DNAJB6a modulation of cellular sensitivity to AKT inhibition in ESCC 
and AKT signaling regulation in other types of cells. (A) Summary of in vitro cell 
viability test of cells with DNAJB6a over-expression or DNAJB6a knockdown 
showing cellular sensitivity to AKT inhibition (AKTi) and MEK inhibition (MEKi). 
ctrl: DMSO treatment. **: P<.01; n.s.: not statically significant. (B) Western 
blotting showed that modulation of DNAJB6a expression regulates AKT 
signaling only in a subgroup of cell lines tested (Responsive versus 
Non-responsive). VA: vector-alone; Da: DNAJB6a; ctrl: non-targeting control 
oligo; shDa: DNAJB6a knockdown. (C) Proposed model illustrating the 
mechanism of tumor suppression of DNJAB6a in ESCC. 
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Table Legend 
Table 1. Univariate and multivariable survival analyses of clinical parameters 
and nuclear expression of DNAJB6 protein. CI: Confidence interval; HR: 
hazard ratio. HR larger than 1 indicates poor prognostic effect and vice versa. a: 
HR=0.621 indicates patients with high DNAJB6 levels have better prognosis 
than patients with low levels; b: HR=2.019 indicates late stage (III/IV) patients 
have worse prognosis than early stage (I/II) patients. 
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Univariate survival analyses  
 Median 
(Month) 
95% CI p-value 
Nuclear DNAJB6 level   .004 
High expression 19.2 15.6-23.0 
Low expression 12.6 9.8-15.4 
Pathological stage   <.0005 
I & II 24.4 12.0-36.8 
III & IV 11.3 9.1-13.4 
T stage   .174 
T1 & 2 24.3 13.7-34.9 
T3 & 4 14.1 10.7-17.4 
Lymph node metastasis   .003 
Positive 12.2 8.1-16.3 
Negative 23.1 15.1-31.0 
M stage   .025 
M0 16.0 13.3-18.6  
M1/1a/1b 6.3 5.7-6.8  
Grade   .542 
G1 (Well-differentiated) 13.2 6.7-20.0 
G2 (Moderately differentiated) 14.3 10.6-18.0 
G3 (Poorly differentiated) 19.6 15.4-23.8 
Multivariate survival analyses 
   HR 95% CI p-value 
Nuclear DNAJB6 level .621a 0.409-0.943 .025 
Pathological stage 2.019b 1.105-3.689 .022 
Lymph node metastasis .958  0.537-1.710 .886 
M stage 1.340  0.676-2.657 .402 
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Supplementary Materials and Methods 
Tissue microarray (TMA) and immunohistochemical (IHC) staining 
In this study two sets of TMAs from Hong Kong were utilized. All tumor 
specimens were obtained in Hong Kong Queen Mary Hospital from 
esophagectomies performed on patients, who had not received any 
pre-operative chemo-radiotherapy. Firstly, a total of 72 primary ESCC 
specimens collected from 1998 to 2005, together with 25 lymph node 
metastasis specimens from a subset of the 72 patients (Male/female=58/14; 
median age=63.5; T-stage T1-2/T3-4=13/59; N-stage N0/N1/2/3=47/25; M-stage 
M0/M1=62/10; Pathological-stage p1-2/p3-4=30/42; 
Grade-well/moderate/poor=11/42/19) from a previously constructed TMA were 
used.1, 2 A second TMA is comprised of 88 primary ESCC specimens collected 
from 1991 to 1998 from 88 patients (Male/female=74/14; median age=65; 
T1-2/T3-4=7/81; N0/N1/2/3=52/36; M0/M1=86/2; p1-2/p3-44=25/63; 
Grade-well/moderate/poor=28/43/17) and was constructed as described.3 All 
samples were collected prospectively and consecutively. For TMA construction, 
collected samples were included randomly with balance of advanced and 
early stage samples.  
IHC staining was performed and analyzed as previously described.1, 2 DNAJB6 
antibody (M01, Abnova, Taiwan) (1:100 dilution) was used as the primary 
antibody and recognizes both isoforms in Western blotting. Specific nuclear 
DNAJB6 staining intensity was examined and scored by two pathologists 
(KWC and AKYL), who were blinded as to the clinicopathological data of the 
patients. Cytoplasmic staining signal was not evaluated due to non-specific 
staining patterns as judged by both pathologists. The intensity of nuclear 
staining signal was scored using an arbitrary scale from 0 to 3, with negative 
(0), weak (1), moderate (2), and strong (3) expression levels, respectively. 
Scores of 0 and 1 were classified as low protein expression level and scores of 
2 and 3 as high level. The sample size required for survival analysis was 
estimated to be minimally 95 (see “Sample size estimation” below for 
calculation); therefore, the results from both TMAs were pooled and analyzed 
together, as all samples were from Hong Kong patients in the same institute 
following the same collection protocol. See Supplementary Table 3 for 
summary. To evaluate the clinical relevance of DNAJB6 in ESCC, IHC staining 
of two TMAs was performed and correlations of nuclear protein level were 
analyzed.  
Chemical reagents 
All chemical reagents used in this study were purchased from Sigma-Aldrich 
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Corporation (St. Louis, MO, USA) unless otherwise stated. 
Cell lines 
Sixteen ESCC cell lines, two immortalized esophageal epithelial cell lines, one 
immortalized nasopharyngeal epithelial cell line, and seven cell lines of other 
types of cancer were used (Supplementary Table 4).4-20 KYSE30TSI was 
established from a subcutaneous tumor of a mouse injected subcutaneously 
with KYSE30. KYSE70TS was established from a tumor of a mouse injected 
subcutaneously with KYSE70.KYSE150Luc is a KYSE150 cell line labeled 
with firefly luciferase.21 Cells were cultured as described.22 Cells were routinely 
tested for mycoplasma contamination by both DAPI staining and PCR 
amplification of DNA. 
Plasmids 
The protein coding sequences from the plasmid pEGFP-N1-DNAJB6aWT 
(NCBI Reference Sequence: NM_058246.3), 
pIRES2-EGFP-HA-DNAJB6a-HPD(MUT) (mutated DNAJB6a in which the 
HPD motif, amino acids 31 to 33, were mutated to AAA), 
pIRES2-EGFP-HA-DNAJB6a-∆J (mutated DNAJB6ain which the DNAJ 
domain, amino acids 1 to 75, were removed), and the pRK5-Myc-DNAJB6bWT 
(NM_005494.2)were cut and ligated to corresponding vectors. The 
DNAJB6a-∆NLS and DNAJB6b-∆NES constructs were generated by fusion 
Polymerase Chain Reaction (PCR); the NLS sequence from amino acids 305 
to 319 (KRKKQKQREESKKKK) of DNAJB6aand the NES sequence from 
amino acids 223-229 (LKSLTIN)of DNAJB6b were removed. In general, the 
pEGFP-N1 (Clontech, Mountain View, CA, USA) was used for subcellular 
localization study. The pWPI lentiviral expression vector (Addgene plasmid 
12254) was used to express the gene of interest in cell lines. The pLKO.1 
lentiviral shRNA vector (Addgene Plasmid 10878) was used for shRNA 
silencing in cell lines. Hairpin sequences targeting DNAJB6 were obtained 
from The RNAi consortium (http://www.broadinstitute.org/rnai/public/). The 
pLKO.1 vector with non-targeting scrambled oligo (Addgene Plasmid 1864) 
served as a control for silencing studies. The lentiCRISPR genome 
engineering vector (Addgene Plasmid 49535) was used for protein expression 
interference assay in cell lines. Target genomic sequences and cloning primers 
were designed using CRISPR Design (http://crispr.mit.edu/). Non-targeting 
sgRNA (sequence: GTTCCGCGTTACATAACTTA) was used as negative 
control as described23. The primers for molecular cloning and sequences for 
shRNA and sgRNA are listed in Supplementary Table 5. A plasmid encoding 
myr-tagged AKT1 (Addgene Plasmid 46969) was used to express 
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constitutively active AKT1 in DNAJB6a over-expressing cells. For 
co-immunoprecipitation using anti-HA antibody, plasmids encoding HA-tagged 
DNAJB6 were generated by inserting the HA-tag coding sequence 
(TACCCATACGACGTCCCAGACTACGCT) at the N-terminus of DNAJB6 in 
the pWPI-DNAJB6 vectors. 
Fusion PCR 
Initial pre-fusion PCR reactions were performed using A/C primers set and B/D 
primers set for amplification of the sequences before the deletion and after the 
deletion, respectively, using the same annealing temperature 55ºC (see 
Supplementary Table 5 for primer identification). The two fragments were then 
gel-purified using QIAquick Gel Extraction Kit (Qiagen N.V., Venlo, 
Netherlands) and served as the templates for the following fusion PCR 
reaction, which was performed using A/B primers set and the two fragments 
purified as templates with the following cycles (95ºC 1', 50ºC 3', repeat 4 times) 
prior to regular PCR cycles (95ºC 30'', 55ºC 1', 72ºC 30'', repeat 30 times). 
Lentivirus preparation and infection  
For lentiviral infection, the pWPI vector containing the gene of interest,  
pLKO.1 vector containing the hairpin sequences, or lentiCRISPR vector 
containing targeted RNA sequences were used together with the packaging 
vector psPAX2 (Addgene plasmid 12260) and the envelope vector pMD2.G 
(Addgene plasmid 12259). The human embryonic kidney HEK293T cell line 
was used as the packaging cell line. The HEK293T cells were seeded 
overnight for transfection. The pWPI/pLKO.1/lentiCRISPR/pLVX-EF1a, 
psPAX2, and pMD2.G vectors were mixed in a ratio of 4:3:1 in weight 
(8µg/6µg/2µg) (for a tissue culture T-75 flask) and transfected using FuGENE 
HD transfection reagent (Promega, Madison, WI, USA) following the protocol 
from the manufacturer. Three DNAJB6a silencing oligos were used to transfect 
HEK293T cells all together to generate a pool of viruses containing all three 
oligos. Cells were kept three days without changing medium. The supernatant 
was then filtered using 0.45µm syringe filter (Pall, Port Washington, NY, USA). 
After infection, cells at passages 3~7 were used for assays.  
Fluorescent fusion protein-based subcellular localization assay 
Mutant forms of DNAJB6a/b were generated by fusion PCR as described 
above. The constructs were then fused to an enhanced green fluorescent 
protein at the C-terminal end using the pEGFP-N1 vector. The fusion proteins 
were transiently expressed in ESCC cell lines by DNA transfection using 
FuGENE HD transfection following manufacturer’s protocol. The fluorescent 
signals indicating the subcellular localizations of the fusion proteins were 
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monitored and recorded using the Eclipse Ti florescent microscope (Nikon, 
Melville, NY) equipped with SPOT RT digital camera (Diagnostic Instruments, 
Inc., Sterling Heights, MI). 
In vivo tumorigenicity assay 
Female BALB/c/nu/nu athymic nude mice (6-8 weeks of age) were obtained 
from the Laboratory Animal Unit of the University of Hong Kong. All 
experimental procedures were approved by the Committee on the Use of Live 
Animals in Teaching and Research in the University of Hong Kong. The 
tumorigenicity of cell lines was tested in nude mouse tumorigenicity assays. In 
general, cell numbers (1x106 for KYSE30TSI, 1.5x106 for KYSE70TS, 1x107 
with 1:1 Matrigel (BD Bioscience, San Jose, CA, USA) for KYSE140, 5x106 
with 1:1 Matrigel for KYSE510, 4.5x106 for KYSE450, and 5x106 with 1:1 
Matrigel for T.Tn), were injected subcutaneously into one flank of the mice, in a 
group of six mice per cell line. Tumor growth was monitored weekly by 
measuring the size using a caliper. Mice of the same group were culled and 
terminated if one of them developed severe tumor ulceration. 
Experimental metastasis mouse model 
For DNAJB6 metastasis assay, a total of 1x106 KYSE150Luc cells with 
DNAJB6a/b over-expression were injected intravenously through the tail vein 
of female 6-8 weeks old athymic nude mice in a group of six mice per cell line. 
For TS1/TS2 metastasis assay, a total of 1.5x106 cells were injected. Mice 
were then monitored by measuring bioluminescent signals using the Xenogen 
IVIS 100 System (PerkinElmer, Waltham, MA, USA) as described.21 Mice 
survival data were also recorded.  
RNA isolation and real-time quantitative PCR (QPCR) 
RNA isolation, reverse transcription, and QPCR were performed as 
described.24 For the Taqman assay for measuring expression of DNAJB6a, the 
gene-specific Taqman probe (Gene Expression Assay Hs00369717_m1, 
Applied Biosystems) was used. For the UPL QPCR assay for measuring 
DNAJB6bexpression, forward primer (TGGCAGAAAAATCACTACAAAGAG) 
and reverse primer (TGCGTGCGTTGAATTACTTG) with UPL probe #68 
(Roche Applied Science) were used. The Applied Biosystems® Human GAPD 
Endogenous Control (Invitrogen, Carlsbad, CA, USA) was used for equal 
loading control. Experiments were repeated three times independently. 
Expression with average fold-changes larger than 2 or smaller than 0.5 are 
considered altered. 
Western blotting analysis 
Western blot analysis was performed according to modified standard protocol 
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as described.25 Antibodies used are listed in Supplementary Table 6. 
Western blotting analysis on tumors from subcutaneous injection of 
mice 
Cells were injected subcutaneously into nude mice. When tumors reached 
around 50-100mm3in size, mice were killed and tumors were collected with 
minimal mice tissue contamination. Tumors were homogenized and lysed 
followed by procedures of Western blotting. 
Flow cytometry cell cycle analysis 
For synchronized G1/S transition regulation study, cells were seeded for 2 
days and reached ~25-40 % confluence before incubation with serum-free 
medium for 72 hours to synchronize cells in the G1 phase. For synchronized 
G2/M transition regulation study, cells were seeded in culture flasks for 2 days 
before incubation with serum-containing medium with 2.5mM Thymidine for 24 
hours. Cells were then released from the block for 3 hours by replacing with 
fresh serum-containing medium, followed by incubation with serum-containing 
medium with 50ng/mL nocodazole for 14 hours to synchronize cells in mitosis. 
Cells were then released by replacing with fresh medium. Flow cytometry 
analysis was performed as described.26 
Cell proliferation assay 
The proliferation and viability of cells were determined by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as 
described.27 
MTT proliferation assay with AKTi treatment 
The Akt Inhibitor XIII (Merck Millipore, Darmstadt, Germany) was dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 13.3mM as stock. Cells were 
counted and seeded in triplicate in 96-well cell culture microplates. Fresh 
medium with 10% FBS and stated concentration of Akt inhibitor was added on 
Day 2. Measurements were taken on Day 4 as described above. Medium 
containing equally diluted DMSO was added to control cells. 
Inhibitor assay 
For Western blotting analysis, Akt Inhibitor was added into culture medium to 
the stated concentrations. Cells were seeded in 6-well plates overnight before 
incubation in Akt Inhibitor-containing medium overnight, followed by lysis 
preparation for Western blotting analysis. Medium containing equally diluted 
DMSO was added to control cells. For cellular sensitivity assessment, 3.5 µM 
Akt Inhibitor XIII for AKTi and 80 µM U0126 for MEKi were applied.. 
Insulin-like growth factor 1 (IGF-1) treatment 
The recombinant human IGF-1 (PeproTech, Rocky Hill, NJ, USA) was added 
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into culture medium to the stated concentrations. Cells were seeded in 6-well 
plates overnight before incubation in IGF-1-containing medium overnight. 
Okadaic acid treatment 
Cells were seeded in 6-well plates over two nights and were incubated in 
20µM okadiac acid for 1.5 hours before lysate collection. Medium containing 
equally diluted DMSO was added to control cells. 
Near-infrared (NIR) fluorescent protein-based protein-protein interaction 
assay 
The PAS/GAFm domains of iRFP were amplified from Addgene plasmids 
#39867 and #39868, respectively. A glycine-rich linker (DNA sequence: gga 
ggc ggg gga agc ggc gga ggc ggg tcc) was added to the C-terminus of PAS or 
the N-terminus of GAFm for further cloning. Constructs of protein pairs of 
interest, as indicated in text, were ligated to PAS/GAFm domains by fusion 
PCR, inserted into pLVX-EF1a (modified from pLVX-CMV, Clontech) lentiviral 
expression vector, and co-expressed by viral infections in KYSE30TSI cells. 
The pWPI vector encoding EGFP was co-expressed to mark the cell border. 
Live cell fluorescence images were acquired using the Carl Zeiss LSM 510 
confocal microscopy (Oberkochen, Germany). The NIR fluorescent signal 
indicates the PAS and GAFm domains are present in close proximity, 
suggesting interaction/complexing between the two fusion proteins of interest. 
AKT1-wild type (WT) construct and AKT1-MAA mutant construct 
(K179M/T308A/S473A) were amplified from Addgene plasmids #9021 and 
#9031, respectively. The NIR fluorescence signal-positive cell percentage was 
calculated by averaging individual percentages (NIR-positive cell 
number/GFP-positive cell number) from 3 confocal microscopic images.  
Co-immunoprecipitation (CoIP) assay 
CoIP assay was performed according to the protocol from Abcam (Cambridge, 
UK) (http://www.abcam.com/protocols/immunoprecipitation-protocol-1), using 
non-denaturing buffer and recombinant protein G agarose (Invitrogen). 
Antibodies used are listed in Supplementary Table 6.  
Microarray data analysis 
Microarray data were downloaded from the GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) using the accession number as indicated. 
Microarray data was extracted using MeV: MultiExperiment Viewer 
(http://www.tm4.org/mev.html). 
Sample size estimation 
The sample size required for the survival analysis using the Cox model was 
estimated using the formula shown below28, where α is the rate of type I error 
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(significance level), β is the rate of type II error, 1-β is the power of the analysis, 
ϕ is the probability of the uncensored observation, p is the frequency of high 
expression of DNAJB6, and θ is the expected hazard ratio. In this study, the 
patient cohort had a death rate of 68.8% (ϕ=68.8%). We expected a hazard 
ratio of 0.5 (θ=0.5), a power of the analysis (1-β)=80%, and significance level 
α=0.05. The hazard ratio<1 is defined as the decrease of risk of death in the 
patients with high expression of DNAJB6 compared to the patients with low 
expression of DNAJB6. The total number of patients required for the analysis 
with 20%, 30%, 40% and 50% of high expression of DNAJB6 is 149, 113, 99, 
and 95, respectively. 
 
Statistical analysis 
Statistical analyses for TMA were performed using the SPSS 19 statistical 
software package (IBM Corporation, Armonk, NY). Patient overall survival time 
was defined as the time elapsed from diagnosis to death with censoring of 
patients who died due to non-cancer related causes. Kaplan-Meier analysis 
was used for survival curves with log-rank tests for survival comparisons 
between groups. Univariate Cox proportional hazards model was applied to 
examine the association between overall survival and DNAJB6 expression, as 
well as other clinical parameters. In the multivariable survival analysis, factors 
that showed significant association with survival by the Kaplan-Meier analysis 
were included in the model. All the parameters were verified for the 
assumptions of the Cox model using R package.29 The chi-square test was 
used for testing the association of nuclear DNAJB6 level with other clinical 
parameters. For other statistical analyses, the Student’s t-test was used unless 
stated otherwise. A p-value less than 0.05 was considered statistically 
significant. All tests of significance were 2-sided. The error bars shown in the 
figures represent one standard deviation from the mean. For multiple-test 
comparisons, the p value was adjusted using false discovery rate method.30 An 
adjusted p-value less than 0.05 is considered significant. An adjusted p-value 
less than 0.1 is considered marginally significant. 
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Supplementary Figure Legends 
Supplementary Figure 1.Representative images of TMA DNAJB6 nuclear 
staining pattern in EC specimens. Scale: 400X. 
Supplementary Figure 2. Kaplan-Meier survival analysis showed that 
presence of lymph node metastasis was a prognostic marker.  
Supplementary Figure 3. Kaplan-Meier survival analysis showed that nuclear 
DNAJB6 level was a prognostic marker for better survival in patients without 
lymph node metastasis.  
Supplementary Figure 4. Schematic diagram of DNAJB6a and DNAJB6b. 
The two variants differ in the very C-terminal. DnaJ: J-domain; G/F: 
Glycine-Phenylalanine Rich Region; NES: nuclear export signal; NLS: nuclear 
localization signal. 
Supplementary Figure 5. Fluorescence microscopy imaging showed that WT 
DNAJB6a localizes to the nucleus, with the intact NLS and WT DNAJB6b 
diffuses through the cells, but becomes more nuclear when the NES is 
removed. Scale bar = 50 µm. 
Supplementary Figure 6. Western blotting confirmed the expression of 
GFP-fusion mutant and WT DNAJB6a/b proteins in KYSE150 and KYSE30. 
Asterisk: bands indicating fusion protein expression. 
Supplementary Figure 7.RNA expression profile of DNAJB6a and 
DNAJB6bin a panel of ESCC cell lines, as compared to immortalized normal 
esophageal epithelial cell line NE3. Only DNAJB6a expression is 
down-regulated in cancer cell lines compared to NE cells. The expression 
profile of NE083 was also provided as a reference. 
Supplementary Figure 8.Tumor growth curves of the four EC cell lines 
over-expressing WT DNAJB6a/b and mis-localized DNAJB6a mutant in nude 
mouse tumorigenicity assay. Only WT nucleus-localized DNAJB6a 
over-expression suppresses tumor growth. 
Supplementary Figure 9. Western blotting confirmed the expression of WT 
and mutant DNAJB6a/b proteins in the four cell lines for tumorigenicity assay. 
Supplementary Figure 10. Tumor growth curves of the two EC cell lines with 
DNAJB6a silenced in nude mouse tumorigenicity assay. DNAJB6a silencing 
promotes tumor growth. ctrl: non-targeting control oligo. 
Supplementary Figure 11. In vitro cell proliferation curves of KYSE510 and 
KSYE30TSI cells with WT and mutant DNAJB6a/b over-expression. Only WT 
nucleus-localized DNAJB6a over-expression suppresses cell proliferation.  
Supplementary Figure 12. In vitro cell proliferation curves of KYSE450 and 
T.Tn cells with DNAJB6a silenced. DNAJB6a silencing enhances cell 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 9 of 14 
 
proliferation. ctrl: non-targeting control oligo.  
Supplementary Figure 13. Cell cycle progression after release from mitotic 
synchronization. DNAJB6a over-expressing KYSE30TSI cells or control cells 
progress toward G1 at a comparable rate. Recovery time: 2 hours. 
Supplementary Figure 14. In vitro cell proliferation curves of KYSE450 and 
T.Tn with DNAJB6a expression interfered. Loss of DNAJB6a enhances cell 
proliferation. ctrl: non-targeting control oligo; sgRNA1 and sgRNA2: sgRNA 
specifically target DNAJB6a. 
Supplementary Figure 15. In vitro cell proliferation curves of KYSE510 and 
KYSE30TSI with DNAJB6a expression and constitutively active AKT1 
expression. Akt activity rescue greatly diminishes the inhibitory effect of 
DNAJB6a on cell proliferation. myrAKT: myr-tagged constitutively active AKT1 
construct. 
Supplementary Figure 16. Tumor growth curves of KYSE510 and 
KYSE30TSI cells over-expressing WT and mutant DNAJB6a in nude mouse 
tumorigenicity assay. Only over-expression of WT DNAJB6a with intact HPD 
motif suppresses tumor growth. 
Supplementary Figure 17. In vitro cell proliferation curves of KYSE510 and 
KSYE30TSI cells with WT and mutant DNAJB6a over-expression. Only 
over-expression of WT DNAJB6a with intact HPD motif suppresses cell 
proliferation. 
Supplementary Figure 18. Representative fluorescence images showing 
complexing of AKT1 and DNAJB6a in vitro. Co-expression of PAS-AKT1WT 
and DNAJB6a-GAFm fusion proteins produce NIR fluorescent signal, 
suggesting WT DNAJB6a complexes with WT AKT1. Introduction of either 
mutant (DNAJB6aAAA or AKT1MAA) fusion proteins diminishes the formation 
of complexes, as indicated by the absence of NIR signals 
(PAS-AKT1MAA/DNAJB6aWT-GAFM and 
PAS-AKT1WT/DNAJB6aAAA-GAFm). GFP signals show cell borders and NIR 
signals (red pseudocolor) indicate potential protein-protein 
interaction/complexing. Scale bar = 100 µm.  
Supplementary Figure 19. Expressions of DNAJB6a transcripts in other 
cancer types. **: P < .01; n.s.: P > .05. All expression levels were normalized to 
that of the normal tissue for each cancer type, respectively. Data source: 
GSE1420 for EAC, GSE41804 for liver cancer, Bhattacharjee, A., et al.,31 for 
lung cancer, GSE7803 for cervical cancer, and GSE32323 for colorectal 
cancer. 
Supplementary Figure 20. Bioluminescent images of mice tail-vein injected 
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with DNAJB6a- over-expressing cells and vector-alone control cells. 
DNAJB6a- over-expressing cells show comparable lung colonization as the 
control cells.  
Supplementary Figure 21. Bioluminescent intensities of mice tail-vein 
injected with DNAJB6a-over-expressing cells and vector-alone control cells. 
No significant differences were detected between the two groups.  
Supplementary Figure 22. Survival curves of mice injected with DNAJB6- 
over-expressing cells and vector-alone control cells. Both groups of mice show 
comparable survival profiles. 
Supplementary Figure 23. Co-immunoprecipitation assay confirming 
interaction between HSP70 and DNAJB6 in KYSE30TSI cells over-expressing 
HA-tagged DNAJB6. Anti-HA antibody was used to immunoprecipitate the 
HSP70/DNAJB6 complex. IP: immunoprecipitation; IB: immunoblotting; VA: 
vector-alone; Db: DNAJB6b; Da: DNAJB6a. Alpha-tubulin was used as a 
loading control and IP control. 
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Supplementary Table Legends 
Supplementary Table 1. Interaction tests between nuclear DNAJB6 level and 
other prognostic clinicopathological parameters by Cox regression analysis. 
Supplementary Table 2. Correlation analyses between nuclear DNAJB6 level 
and other clinicopathological parameters. P-value was calculated by Pearson 
Chi-square or Fisher's exact test, if values in any of the cells were below 5. 
Supplementary Table 3. TMA clinicopathological parameters. 
Supplementary Table 4. Cell lines used. 
Supplementary Table 5. Primers and oligos used in molecular cloning. 
Supplementary Table 6. Antibodies used. 
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Supplementary Table 1
 HR (95%CI) p-value 
DNAJB6 & Pathological stage 
DNAJB6 0.486 (0.237-0.999) <.05 
Pathological stage 1.767 (1.031-3.029) .038 
DNAJB6 x Pathological stage 1.370 (0.587-3.197) .467 
DNAJB6 & Lymph node metastasis 
DNAJB6 0.377 (0.195-0.731) .004 
Lymph node metastasis 1.137 (0.681-1.901) .623 
DNAJB6 x Lymph node metastasis 2.252 (1.001-5.066) <.05 
DNAJB6 & M stage 
DNAJB6 0.502 (0.332-0.760) .001 
M stage 1.014 (0.438-2.348) .975 
DNAJB6 x M stage 16.721 (4.110-68.025) <.0005 
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 High nuclear 
DNAJB6  
(No. / %) 
Low nuclear 
DNAJB6  
(No. / %) 
p-value # 
(2-sided) 
Lymph node metastasis   .022 
positive 35/51.5  64/69.6   
negative 33/48.5  28/30.4   
Pathological stage   .242 
I & II  27/39.7  28/30.4   
III & IV 41/60.3  64/69.6   
T stage      .630 
T1 & 2 7/10.3  13/14.1   
T3 & 4 61/89.7  79/85.9   
M stage      .560 
M0 64/94.1  84/91.3   
M1/1a/1b 4/5.9  8/8.7   
Grade      .129 
G1 (Well-differentiated)   22/32.4  17/18.5   
G2 (Moderately differentiated) 32/47.1  53/57.6   
G3 (Poorly differentiated) 14/20.5  22/23.9   
#: calculated by Chi-squared test 
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 TMA1 (N = 72)#  (No. / %) TMA2 (N=88)#  (No. / %) Combined (N=160)#  (No. / %) 
Gender    
  Male 58/80.6  74/84.1  132/82.5  
  Female 14/19.4  14/15.9  28/17.5  
  Total 72 88 160 
Age of onset    
Median age (range) 68.5 (41-87) 63 (39-83) 65 (39-87) 
Tissue type    
  Primary Tumor 
  Lymph node metastasis 
72/74.2  
25/25.8  
88/100  
0 
160/86.5  
25/13.5  
  Total 97* 88 185 
T stage    
  T1 2/2.8  4/4.6  6/3.8  
  T2 11/15.3  3/3.4  14/8.8  
  T3 45/62.5  60/68.2  105/65.6  
  T4 14/19.4  21/23.8  35/21.9  
  Total 72 88 160 
M stage    
  M0 62/86.1  86/97.7  148/92.5  
  M1 10/13.9  2/2.3  12/7.5  
  Total 72 88 160 
Pathological stage 
  I 
 
0 
 
7/8.0  
 
7/4.4  
  II 
  III 
  IV 
  Total 
Grade 
30/41.7  
32/44.4  
10/13.9  
72 
18/20.5  
61/69.2  
2/2.3  
88 
48/30  
93/58.1  
12/7.5  
160 
  Well 11/15.3  28/33.0  39/24.4  
  Moderate 
  Poor 
  Total 
Lymph node metastasis 
  Positive 
  Negative 
  Total 
Nuclear DNAJB6 staining 
  Higher expression 
  Lower expression 
  Total 
42/58.3  
19/26.4  
72 
 
47/65.3  
25/34.7  
72 
 
53/73.6  
19/26.4  
72 
43/47.7   
17/19.3  
88 
 
52/59.1  
36/40.9  
88 
 
39/44.3  
49/55.7  
88 
85/53.1  
36/22.5  
160 
 
99/61.9  
61/38.1  
160 
 
92/57.5  
68/42.5  
160 
#: number of patients enrolled 
*: total samples from 72 patients 
   
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplementary Table 4
Cell Line Description Culture medium 
NE3 Immortalized normal 
esophageal epithelial cells 
50% Defined Keratinocyte-SFM + 50% EpiLife®  
NE083 
81-T ESCC Roswell Park Memorial Institute medium (RPMI) 
with 10% Fetal bovine serum (FBS) 
EC1 
RPMI with 10% FBS 
EC18 
HKESC-2 Dulbecco's Modified Eagle medium (DMEM) with 
5% FBS and 5% Newborn Calf Serum (NCS) 
KYSE30 
RPMI with 10% FBS 
KYSE70 
KYSE140 
KYSE150 
KYSE180 
KYSE270 
KYSE410 
KYSE450 
KYSE510 
KYSE520 
SLMT-1 DMEM with 5% FBS and 5% NCS 
T.Tn RPMI with 10% FBS 
A549 Lung adenocarcinoma 
DMEM with 5% FBS and 5% NCS 
BOWES Melanoma 
HeLa Cervix carcinoma 
HepG2 Hepatocellular carcinoma 
HONE-1 Nasopharyngeal carcinoma 
SW480 Colon adenocarcinoma RPMI with 10% FBS 
HT1080 Fibrosarcoma DMEM with 5% FBS and 5% NCS 
NP460 Immortalized normal 
nasopharyngeal epithelial cells 
50% Defined Keratinocyte-SFM + 50% EpiLife®  
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TRC c lone IDTarget sequence Forward Sequence / Reverse Sequence
CCGGTCGATATCAACTTCAACTAAACTGCAGTTTAGTTGAAGTTGATATCGATTTTTG
AATTCAAAAATCGATATCAACTTCAACTAAACTGCAGTTTAGTTGAAGTTGATATCGA
CCGGCGGGACATCTATGACAAATATCTGCAGATATTTGTCATAGATGTCCCGTTTTTG
AATTCAAAAACGGGACATCTATGACAAATATCTGCAGATATTTGTCATAGATGTCCCG
CCGGTGATTGTTGGGACCACATAATCTGCAGATTATGTGGTCCCAACAATCATTTTTG
AATTCAAAAATGATTGTTGGGACCACATAATCTGCAGATTATGTGGTCCCAACAATCA
Target Genomic  sequence Forward Sequence / Reverse Sequence
CACCG TAAGGAGCAGCTGCTGCGCT
AAAC AGCGCAGCAGCTGCTCCTTA C
CACCG TAAGGAGCAGCTGCTGCGCT
AAAC AGCGCAGCAGCTGCTCCTTA C
CACC GACCCCCTCGCGTCCGCAGC
AAAC GCTGCGGACGCGAGGGGGTC 
Cons truc tName Pr imer  Sequence
N-terminus F (A) GGAATTCGCCACCATGGTGGATTACTATGAAGTTCTA
delNLS R (C) GTGATTGCCTTTGGTCGAGCCACCTTCTTTCAATCCTGCT
delNLS F (D) GGATTGAAAGAAGGTGGCTCGACCAAAGGCAATCACTAG
C-terminus R (B) GGGATCCGCCACCCTAGTGATTGCCTTTGGTCGA
N-terminus F (A) GGAATTCGCCACCATGGTGGATTACTATGAAGTTCTA
delNES R (C) CAGCAGCTGCTCCTTACCCTGGCCATCTTCTTCAACTTCTAC
delNES F (D) GTTGAAGAAGATGGCCAGGGTAAGGAGCAGCTGCTGC
C-terminus R (B) CGGGATCCTTACTTGTTATCCAAGCGCAGC
TAAGGAGCAGCTG
CTGCGCT TGG
DNAJB6a
GCTGAGGAGCGCA
TGCGGAG AGG
DNAJB6 shRNA s ilenc ing oligos
DNAJB6b
ΔNES
Cloning pr imers  for  DNAJB6 mutant cons truc ts
TRCN000
0293467
TRCN000
0008778
TRCN000
0293469
TCGATATCAACTTC
AACTAAA
CGGGACATCTATGA
CAAATAT
TGATTGTTGGGACC
ACATAAT
DNAJB6a
ΔNLS
DNAJB6a
GACCCCCTCGCGT
CCGCAGC AGG
DNAJB6 CRISPR targeting oligos
DNAJB6b
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Supplementary Table 6
Antibody target Vendor Catolog No.
DNAJB6 Genetex GTX101947
p84 Genetex GTX70220
GAPDH Genetex GTX100118
cyclin E1 Santa Cruz sc-247
AKT1 T308 phosphorylation Cell Signaling #4056
AKT1 S473 phosphorylation Cell Signaling #4058
AKT1 total form Cell Signaling #9272
p27KIP1 Genetex GTX100446
Rabbit IgG antibody (HRP) Genetex GTX213110-01
Mouse IgG antibody (HRP) Genetex GTX213111-01
Anti-HA antibody Sigma-Aldrich H3663
Alpha-tubulin Genetex GTX108784
HSP70 Genetex GTX111088
